| Gene name: | RELA |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | Pancreata |
| Cell name: | Human low-grade PanIN cell |
| Gene ID: | 5970 |
| Category: | protein coding |
| Phenotype: | Pancreatic ductal adenocarcinoma |
| Experimental category: | HL |
| PMID: | 27454298 |
| Experiment: | Western blot//SA-β-gal activity assay//qPT-PCR |
| Description: | Quantification of SA-β-Gal–positive cells in low-grade mPanIN lesions from Kras and Kras RelA mice demonstrated loss of SA-β-Gal activity in Kras RelA mPanIN.In addition, the senescence marker decoy receptor 2 (DCR2; also known as TNFRSF10D) was significantly lower in Kras RelA pancreata than in Kras pancreata on both an mRNA expression and a protein level.GSEA demonstrated a loss of the SASP signature in Kras RelA mice. |
| Target gene: | CXCL1 |
| Official symbol(s): | CXCL1 |
| R-AG-Target gene: | -- |
| Subcategory: | Unclear |
| Target gene experiment: | Western blot//SA-β-gal activity assay |
| Target gene description: | Of the 40 cytokines and chemokines represented in this panel, CXCL1 (also known as KC) was most robustly downregulated in PDEC Kras treated with JSH-23. The decrease in CXCL1 protein levels was corroborated by an increased SA-β-Gal activity in PDEC Kras incubated with CXCL1 for 48 hours .In Kras pancreata, Cxcl1 mRNA expression was moderately to strongly present in the cytoplasm of most duct cells in mPanIN lesions, in acinar cells around mPanIN lesions, and in immune cells.Cxcl1 mRNA was present in immune cells, only faintly present in a few duct cells, and absent in the majority of acinar cells in Kras RelA pancreata. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...